When I catch up on a call with Ochre Bio co-founder and chief executive Jack O’Meara, he is awaiting his next connection while returning from Boston on a three-flight journey via the Azores to get back to the UK. Such is the life of a start-up CEO when travel plans go awry. It’s been a week or so since he and his teams in New York, Oxford and Taiwan celebrated a potential billion-dollar partnership deal to develop new regenerative treatments for advanced liver disease with German pharma giant Boehringer Ingelheim.  Headquartered on a bank of the Rhine in Germany’s midwest,…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .